All In Biotech

Drug Trial Radar · NCT06879041

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

Mar 10, 2025

Primary completion

Apr 16, 2029

Study completion Apr 16, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Mar 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Conditions

  • Metastatic Castration-Resistant Prostate Cancer

Interventions

  • AZD2287Drug

    Participants will receive AZD2287

  • AZD2275Drug

    Participants will receive AZD2275

  • AZD2284Drug

    Participants will receive AZD2284

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse event (AEs)Time frame: Part A: Up to Day 28; Part B: Up to 5 years
  2. Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Part B: Up to 84 days of receiving AZD2284
  3. Estimates of residence timeTime frame: Part A: Up to 8 days after a dose of AZD2287
  4. Absorbed radiation doses for AZD2287 and AZD2284Time frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
  5. Compare organ uptake of AZD2287 with and without pre-dose administration of AZD2275Time frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
  6. Tumor uptake of AZD2287 in selected regions of interest on SPECT/CT and/or planar imagesTime frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Palo Alto, California · Not yet recruiting

  • Research Site

    San Diego, California · Not yet recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Metairie, Louisiana · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Rochester, Minnesota · Not yet recruiting

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    East Melbourne, Australia · Recruiting

  • Research Site

    CapeTown, South Africa · Not yet recruiting

  • Research Site

    Durban, South Africa · Withdrawn

  • Research Site

    Pretoria, South Africa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.